COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0CR6E
|
|||
Drug Name |
SSYA10-001
|
|||
Synonyms |
3-[(2-Nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
Target | Top | |||
---|---|---|---|---|
Target(s) | MERS-CoV helicase (Hel) | Target Info | Inhibitor | [1] |
SSYA10-001, a CoV helicase inhibitor, selectively inhibits the unwinding activity but not the ATPase activity of CoV helicase and inhibits a broad range of CoVs, including SARS-CoV and MERS-CoV. | ||||
SARS-CoV helicase (Hel) | Target Info | Inhibitor | [1] | |
SSYA10-001, a CoV helicase inhibitor, selectively inhibits the unwinding activity but not the ATPase activity of CoV helicase and inhibits a broad range of CoVs, including SARS-CoV and MERS-CoV. |
References | Top | |||
---|---|---|---|---|
1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.